Fertility startup Inito has raised $29 million in Collection B funding to scale its at-home well being diagnostics platform and use AI-designed antibodies to unlock new sorts of at-home checks.
When the corporate launched its first fertility monitor in 2021, its objective was to make quantitative fertility hormone testing potential at dwelling.
Whereas customary at-home ovulation checks predict fertile days by monitoring estrogen and Luteinizing hormone (LH), they don’t measure the hormone that confirms your ovulation, which is progesterone metabolite PdG. Inito permits girls to measure estrogen, LH, progesterone (PdG), and FSH on a single check strip. Inito’s AI fashions interpret these ranges to disclose fertility hormone patterns, monitor fertile days, and ensure ovulation.
Quick ahead to at present, the startup has change into a well-liked possibility for girls trying to monitor fertility hormones, analyzing greater than 30 million fertility hormone information factors since 2021.
The startup is now doubling down on its perception that healthcare ought to begin at dwelling, and is working to evolve Inito from a fertility tracker right into a broader hormone and at-home well being diagnostics platform.
Inito is utilizing the brand new funding to put money into and develop AI-engineered antibodies, which it says will enable for the event of recent sorts of checks and enhance the accuracy of current ones.
For context, while you take a check at a lab or a house, antibodies are what bind to the goal molecule (resembling estrogen or testosterone) to supply a sign. Conventional antibodies are grown inside animals after which screened manually within the lab, which could be a gradual and costly course of. Typical antibodies additionally lack the sensitivity to make at-home checks for a lot of biomarkers.
Techcrunch occasion
San Francisco
|
October 13-15, 2026
Inito says AI-designed antibodies change the sport. As a substitute of “raising” antibodies in animals, they are often handled nearly like software program.
“We predict how proteins fold in 3D, design synthetic antibodies using AI, and test millions of variants virtually before making a single one in the lab,” defined Inito co-founder and CTO Varun A Venkatesan in an e mail. “This produces antibodies that are far more sensitive, consistent, and stable than anything developed through traditional methods.”
For Inito, it will unlock the following technology of at-home checks. Venkatesan says the corporate is already utilizing these strategies in R&D and that its wet-lab is displaying promising outcomes.
“The real vision is bigger than adding new tests,” mentioned Inito co-founder and CEO Aayush Rai. “The endgame is to redefine diagnostics altogether. If you want to understand what’s happening inside your body at every life stage and health need, you shouldn’t be limited by clinic appointments, lab schedules, or rigid testing systems. You should be able to measure, track, and get insights about your body from home, with lab-grade confidence.”
Inito desires to increase its imaginative and prescient past a “trying to conceive” platform. Its reader and app will quickly energy checks for being pregnant, menopause, and broader at-home well being monitoring.
“Our long-term roadmap goes far beyond fertility,” mentioned Rai. “We’re building toward a platform that can measure and interpret the full spectrum of hormones that shape health across a lifetime. Pregnancy progression, menopause, and broader endocrine markers like testosterone — all powered by AI antibodies and imaging that sets Inito apart today.”
The corporate goes to make use of a part of the funding to scale manufacturing and develop globally to fulfill rising demand throughout the US and new worldwide markets.
Inito’s newest funding spherical was led by Bertelsmann India Investments and Hearth Ventures. The funding brings Inito’s complete funding to round $45 million. The corporate beforehand raised $6 million in funding led by Hearth Ventures and $9 million from Y Combinator, former Nurx CEO Varsha Rao, and a dozen physicians and household workplaces.
